COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YQ2K
|
|||
| Drug Name |
YS110 mAb clone
|
|||
| Synonyms |
YS110
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1], [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN dipeptidyl peptidase 4 (DPP-4) | Target Info | Blocker | [1], [2] |
| A recombinant humanized IgG1 anti-DPP4 mAb inhibits the MERS Cov infections via inhibiting the MERS-CoV entery. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| 2 | Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013 Dec;87(24):13892-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.